Episode Description
In this episode, we explore two underused antidepressants—vilazodone (Viibryd) and vortioxetine (Trintellix)—that offer important advantages over traditional SSRIs, particularly when it comes to minimizing sexual side effects and weight gain. You’ll learn how these medications work, how to dose them effectively, and where they fit into real-world treatment strategies. By the end, you’ll be able to identify how vilazodone and vortioxetine differ from traditional SSRIs, compare their side effect profiles, understand titration schedules, and determine when to consider them as part of your antidepressant selection framework.
Prefer to listen on the go? This podcast is available for free on Spotify, Apple Podcasts, and wherever you get your podcasts–just search Collaborative Psychiatry QuickTakes.
Learning Objectives
By the end of this episode, you’ll be able to:
- Identify the key differences between vilazodone, vortioxetine, and traditional SSRIs.
- Compare side effect profiles, especially regarding weight gain and sexual dysfunction.
- Apply practical dosing and titration strategies for these two medications.
- Determine where these medications fit in your antidepressant treatment algorithm.
Listen Now
Online Streaming Available to QuickTake and Full Access Members Only
Get full access to the online resources for all QuickTakes by joining as a QuickTake Member. Or, join as a Full Access / CME Member to access all QuickTake content along with all of our comprehensive Audio Courses as they are released.
Clinical Tools and Resources
Mechanism of Action
Vilazodone and Vortioxetine each inhibit serotonin reuptake, like traditional SSRIs, but also modulate other serotonin receptors.
- Vilazodone: SSRI + 5HT-1A partial agonist
- Vortioxetine: SSRI + 5HT-1A agonist and additional serotonin receptor effects
This additional receptor activity may help explain their improved side effect profiles—particularly reduced rates of sexual dysfunction and weight gain.
Clinical Use and Indications
Both medications are FDA-approved for major depressive disorder, but like other serotonergic agents, they are frequently used off-label for a wide range of depressive and anxiety symptoms. They’re appropriate for primary care use even when diagnoses extend beyond MDD (e.g., GAD, PTSD), as long as anxiety and depressive symptoms are prominent.
When to Consider These Medications
While either agent could theoretically be used first-line, they are most commonly used as second-line options after traditional SSRIs or SNRIs due to:
- Limited familiarity in primary care
- Potential insurance barriers (especially with vortioxetine)
- Lack of substantial outcome advantage over SSRIs
They are particularly useful in:
- Patients who report sexual dysfunction or weight gain on SSRIs
- Patients with a history of poor tolerability to SSRIs or multiple failed trials
- Treatment-resistant depression where a mechanistically different agent is warranted
Dosing and Titration
Vilazodone (Viibryd):
- Start: 10 mg daily with food
- After 1 week: increase to 20 mg
- Max dose: 40 mg/day
- Must be taken with food to ensure absorption
Vortioxetine (Trintellix):
- Start: 5 mg daily (with or without food)
- After 1 week: increase to 10 mg
- Max dose: 20 mg/day
- No food requirements; may be easier to adhere to
Neither is associated with QTc prolongation, and both can be dosed in the morning or evening based on tolerability.
Side Effects and Tolerability
Both medications share some initiation effects common to serotonergic agents, including GI upset and headache. However, they are notably less likely to cause:
- Sexual dysfunction
- Weight gain
These side effect advantages may improve long-term adherence and make them appealing options for patients concerned about those specific issues.
Strategic Prescribing
- Vilazodone is off-patent as of 2022, making it more accessible for most patients.
- Vortioxetine remains on-patent and may require prior authorization; best reserved for treatment-resistant cases or when vilazodone is poorly tolerated.
- If a patient responds well to an SSRI, there’s no need to switch. But when switching becomes necessary due to side effects or efficacy, choosing a medication with a cleaner side effect profile can reduce dropout risk.
Disclaimer
The content provided by Collaborative Psychiatry is for educational purposes only and is intended to support, not replace, clinical judgment. This material is not medical advice and does not establish a physician-patient relationship.
The creator of this content has no relevant financial relationships or conflicts of interest to disclose.
If you’ve found this helpful, you can support the project and help us keep it free from outside sponsorship by subscribing, joining the mailing list at collaborative-psychiatry.org, or leaving a rating and review in your podcast app. Every little bit helps!